	US 11,813,305 B2
	Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
Yoram Devary, Jerusalem (IL); and Uziel Sandler, Jerusalem (IL)
Assigned to IMMUNE SYSTEM KEY LTD., Jerusalem (IL)
Filed by IMMUNE SYSTEM KEY LTD., Jerusalem (IL)
Filed on Jan. 25, 2021, as Appl. No. 17/157,126.
Application 17/157,126 is a division of application No. 16/050,255, filed on Jul. 31, 2018, granted, now 10,933,117.
Application 16/050,255 is a continuation in part of application No. PCT/IL2017/050129, filed on Feb. 2, 2017.
Claims priority of provisional application 62/291,190, filed on Feb. 4, 2016.
Prior Publication US 2021/0154262 A1, May 27, 2021
Int. Cl. A61K 38/10 (2006.01); A61K 31/337 (2006.01); A61K 31/704 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); G01N 33/53 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01)

CPC A61K 38/10 (2013.01) [A61K 31/337 (2013.01); A61K 31/704 (2013.01); A61K 38/1709 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12Q 1/6886 (2013.01); G01N 33/53 (2013.01); G01N 33/574 (2013.01); G01N 33/57496 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01)]

7 Claims

1. A method of treatment of cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an isolated peptide comprising the amino acid sequence denoted by SEQ ID NO. 1 or a pharmaceutically acceptable salt of said isolated peptide in combination with an anti-cancer agent, wherein said isolated peptide reduces the standard of care administered dose of said anti-cancer agent, and wherein said anti-cancer agent is an anti-PDL1 antibody.